SRPT SAREPTA THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, SAREPTA THERAPEUTICS INC reported revenue of $401M (down 34.3% from a year earlier), net income of −$4.89M and diluted EPS of −$0.05; over the last four quarters revenue was $1.97B and net income −$137M; for the fiscal year ended December 2025 revenue was $2.20B, up 15.6% on the year before.

SRPT annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $2.20B, gross profit n/a, operating income −$700M, net income −$713M (margin -32.5%), EPS −$7.13
• Fiscal year ended Dec 2024: revenue $1.90B, gross profit n/a, operating income $218M, net income $235M (margin 12.4%), EPS $2.34
• Fiscal year ended Dec 2023: revenue $1.24B, gross profit n/a, operating income −$268M, net income −$536M (margin -43.1%), EPS −$5.80
• Fiscal year ended Dec 2022: revenue $933M, gross profit n/a, operating income −$536M, net income −$703M (margin -75.4%), EPS −$8.03
• Fiscal year ended Dec 2021: revenue $702M, gross profit n/a, operating income −$460M, net income −$419M (margin -59.7%), EPS −$5.15

SRPT quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $401M (down 34.3% year over year), net income −$4.89M, EPS −$0.05
• Quarter ended Mar 31, 2026: revenue $731M (down 1.9% year over year), net income $331M, EPS $2.88
• Quarter ended Dec 31, 2025: revenue $443M (down 32.7% year over year), net income −$412M, EPS −$3.93
• Quarter ended Sep 30, 2025: revenue $399M (down 14.5% year over year), net income −$50.6M, EPS −$0.50
• Quarter ended Jun 30, 2025: revenue $611M (up 68.4% year over year), net income $197M, EPS $1.89
• Quarter ended Mar 31, 2025: revenue $745M (up 80.2% year over year), net income −$448M, EPS −$4.60
• Quarter ended Dec 31, 2024: revenue $658M (up 65.9% year over year), net income $159M, EPS $1.50
• Quarter ended Sep 30, 2024: revenue $467M (up 40.8% year over year), net income $33.6M, EPS $0.34
• Quarter ended Jun 30, 2024: revenue $363M (up 38.9% year over year), net income $6.46M, EPS $0.07
• Quarter ended Mar 31, 2024: revenue $413M (up 63.1% year over year), net income $36.1M, EPS $0.37
• Quarter ended Dec 31, 2023 (from the annual report): revenue $397M (up 53.5% year over year), net income $45.7M, EPS $0.79
• Quarter ended Sep 30, 2023: revenue $332M (up 44.1% year over year), net income −$40.9M, EPS −$0.46
• Quarter ended Jun 30, 2023: revenue $261M (up 11.9% year over year), net income −$23.9M, EPS −$0.27
• Quarter ended Mar 31, 2023: revenue $254M (up 20.2% year over year), net income −$517M, EPS −$5.86
• Quarter ended Dec 31, 2022 (from the annual report): revenue $258M (up 28.3% year over year), net income −$109M, EPS −$1.24
• Quarter ended Sep 30, 2022: revenue $230M (up 21.6% year over year), net income −$258M, EPS −$2.94
• Quarter ended Jun 30, 2022: revenue $233M (up 42.3% year over year), net income −$231M, EPS −$2.65
• Quarter ended Mar 31, 2022: revenue $211M (up 43.5% year over year), net income −$105M, EPS −$1.20
• Quarter ended Dec 31, 2021 (from the annual report): revenue $201M, net income −$122M, EPS −$1.43
• Quarter ended Sep 30, 2021: revenue $189M, net income −$48.1M, EPS −$0.60

SRPT cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$205M, share buybacks $25.0M
• Fiscal year ended Dec 2024: operating cash flow −$206M, share buybacks $0
• Fiscal year ended Dec 2023: operating cash flow −$501M, share buybacks $0
• Fiscal year ended Dec 2022: operating cash flow −$325M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$443M, share buybacks n/a

SRPT balance sheet

• Jun 30, 2026: cash $571M, total assets $3.19B, total liabilities $1.66B, shareholders' equity $1.53B
• Mar 31, 2026: cash $464M, total assets $3.18B, total liabilities $1.67B, shareholders' equity $1.51B
• Dec 31, 2025: cash $801M, total assets $3.35B, total liabilities $2.21B, shareholders' equity $1.14B
• Sep 30, 2025: cash $613M, total assets $3.49B, total liabilities $2.17B, shareholders' equity $1.32B
• Jun 30, 2025: cash $511M, total assets $3.68B, total liabilities $2.32B, shareholders' equity $1.40B
• Mar 31, 2025: cash $241M, total assets $3.47B, total liabilities $2.32B, shareholders' equity $1.19B
• Dec 31, 2024: cash $1.10B, total assets $3.96B, total liabilities $2.44B, shareholders' equity $1.53B
• Sep 30, 2024: cash $198M, total assets $3.60B, total liabilities $2.38B, shareholders' equity $1.22B

What is SRPT's revenue?

SAREPTA THERAPEUTICS INC reported $1.97B of revenue over its last four quarters, through June 30, 2026.

Is SRPT profitable?

No. SAREPTA THERAPEUTICS INC lost $137M over the last four quarters.

What is SRPT's EPS?

Diluted earnings per share over the last four quarters were −$1.60; −$0.05 in the latest quarter.

SRPT ownership and insider trades · All stocks